SCHEMBL352001

SCHEMBL352001

OCC1CN(Cc2ccccc2)CCO1

nearest known ligand 0.71

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 17/20 0.71
DRD2 P14416 4/20 0.65
DRD3 P35462 4/20 0.65
CYP1A2 P05177 1/20 0.63
CYP3A4 P08684 1/20 0.63
CYP2D6 P10635 1/20 0.63
CYP2C9 P11712 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5695486 1.00 DRD4 (0.71) DRD4DRD2DRD3CYP1A2CYP3A4
SCHEMBL1877824 1.00 DRD4 (0.71) DRD4DRD2DRD3CYP1A2CYP3A4
SCHEMBL13229950 0.91 DRD4 (0.59) DRD4DRD2DRD3CYP1A2CYP3A4
SCHEMBL353574 0.89 DRD4 (0.59) DRD4DRD2DRD3CYP1A2CYP3A4
SCHEMBL7371617 0.88 DRD4 (0.76) DRD4DRD2DRD3CYP1A2CYP3A4
SCHEMBL21553759 0.86 DRD4 (0.57) DRD4DRD2DRD3CYP1A2CYP3A4
SCHEMBL17803030 0.86 DRD4 (0.57) DRD4DRD2DRD3CYP1A2CYP3A4
SCHEMBL735729 0.86 DRD4 (0.73) DRD4DRD2DRD3CYP1A2CYP3A4
SCHEMBL2304936 0.86 DRD4 (0.73) DRD4DRD2DRD3CYP1A2CYP3A4
SCHEMBL5748888 0.86 DRD4 (0.73) DRD4DRD2DRD3CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4273143-B1 DERIVATIVE OF 2,5-DIKETOPIPERAZINE COMPOUND, AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF DALIAN WZ PROBIOTICS AD HEALTH CO LTD (CN) 2025-05-21 EP disclosed
US-20240140941-A1 DERIVATIVE OF 2,5-DIKETOPIPERAZINE COMPOUND, AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF DALIAN WZ PROBIOTICS AD HEALTH CO., LTD (CN) 2024-05-02 US disclosed
EP-4273143-A1 DERIVATIVE OF 2,5-DIKETOPIPERAZINE COMPOUND, AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF Dalian WZ Probiotics AD Health Co., Ltd (CN) 2023-11-08 EP disclosed
WO-2023193054-A1 SPLEEN TYROSINE KINASE INHIBITORS UNIQUEST PTY LTD (AU) 2023-10-12 WO disclosed
CN-114685456-B 2, 5-diketopiperazine compound derivative, preparation method thereof, pharmaceutical composition and application thereof 大连万众益生大健康有限公司 2023-10-10 CN disclosed
WO-2022144002-A1 DERIVATIVE OF 2,5-DIKETOPIPERAZINE COMPOUND, AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF 大连万众益生大健康有限公司 2022-07-07 WO disclosed
CN-114685456-A 2, 5-diketopiperazine compound derivative, preparation method thereof, pharmaceutical composition and application thereof 大连万众益生大健康有限公司 2022-07-01 CN disclosed
WO-2021115413-A1 NEUROMUSCULAR-BLOCKING DRUG AND PREPARATION METHOD THEREFOR 江苏恒瑞医药股份有限公司 2021-06-17 WO disclosed
EP-3053923-B1 TRIAZOLOPYRAZINE DERIVATIVES AS TYROSIN KINASE INHIBITORS KOREA RES INST CHEMICAL TECH (KR) 2018-04-11 EP disclosed
EP-2658844-B1 NOVEL PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS SANOFI SA (FR) 2016-10-26 EP disclosed
US-5166203-A QUINOLINECARBOXYLIC ACID DERIVATIVES, ANTIBACTERIAL AGENT CONTAINING THE SAME KANEBO, LTD. (JP) 1992-11-24 US disclosed
CN-1059339-A New quinoline carboxylic acid derivative, the antiseptic-germicide that contains them and their method for making KANEBO LTD (JP) 1992-03-11 CN disclosed
EP-0472826-A2 Novel quinolinecarboxylic acid derivatives, use thereof, antibacterial agent containing the same, process for preparing said compounds and intermediate compound KANEBO LTD. (JP) 1992-03-04 EP disclosed
CN-1049662-A Coumarin derivative, preparation thereof and application thereof in treating cerebrovascular disorder SANKYO CO (JP) 1991-03-06 CN disclosed
EP-0411912-A2 Coumarin derivatives, their preparation and their use in the treatment of cerebrovascular disorders Sankyo Company Limited (JP) 1991-02-06 EP disclosed
EP-0383281-A1 1,2-ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same TOYAMA CHEMICAL CO., LTD. (JP) 1990-08-22 EP disclosed
US-4883874-A Azabicyclic intermediates BEECHAM GROUP PLC. OF BEECHAM HOUSE (GB) 1989-11-28 US disclosed
US-4826839-A GASTROINTESTINAL DISORDERS, HEADACHES BEECHAM GROUP P.L.C. (GB) 1989-05-02 US disclosed
US-4782054-A ANTIISCHEMIC, ANTIHYPOXIC, STIMULANTS ADIR ET COMPAGNIE (FR) 1988-11-01 US disclosed
EP-0226267-A1 Oxa-, thia- and diazabicycloalkane derivatives, process for their preparation and their use as pharmaceuticals BEECHAM GROUP PLC (GB) 1987-06-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240140941-A1 DERIVATIVE OF 2,5-DIKETOPIPERAZINE COMPOUND, AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF WEE1, WEE2, CYP51A1 DRD4 3039/4885DRD2 2445/4885DRD3 3654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.